New research indicates that individuals who come off new GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds much more quickly than those who halt traditional lifestyle programs.
Research printed in a major medical journal shows that while obese people often shed about a fifth of their body weight while undergoing treatment, the weight comes back at an estimated rate of nearly a kilo each month upon discontinuation.
"Users buying such drugs must be aware of the danger of fast weight regain when the therapy is stopped," stated researcher Dr. Susan Jebb.
That rate of regain implies a return to pre-treatment weight within about a year and a half.
Analyzing Approaches
The study, which looked at dozens of studies involving over 9,000 of patients, contrasted the results of the injectable medications with conventional dieting.
Scientists emphasize that people who lose weight through diet and exercise typically experience a less rapid weight regain—approximately 100 grams monthly—after stopping.
Explaining the Quick Regain
Nutrition scientists propose the mechanism of the injections explains the accelerated regain.
The injections mimic a natural hormone called glucagon-like peptide-1, which controls feelings of fullness.
"Long-term administration of the hormone concentrations several times higher than normal might result in the system to generate a reduced amount of its own natural hormone, and may also lessen responsiveness to its actions," explained Dr. Adam Collins, a nutrition expert.
"Stopping of this medication means appetite is uncontrolled, making excessive eating a significant risk."
An Ongoing Condition?
The NHS recommend the jabs for individuals with obesity-related health risks, accompanied by recommended diet and exercise modifications.
A number of clinicians say that, given the significant potential of relapse, the treatment should be considered ongoing.
This view is echoed by pharmaceutical companies, who state that the results "underscore the chronic character of obesity," comparing it to managing diseases like hypertension.
Patient Accounts
Users who have come off the jabs report a powerful resurgence of cravings.
"It was like a switch activating and you're instantly starving," described one woman.
This difficulty is worsened if patients have not established sustainable lifestyle or habit modifications during treatment.
Growing Interest
Recent estimates show that a significant number of adults in the UK have used these injections in the last 12 months, with interest remaining high.
- Adoption is greater among women than men.
- The middle-aged demographic shows the greatest level of interest.
- A large proportion obtain the medications through private prescriptions rather than public health services.
Ultimately, researchers emphasize that while GLP-1 drugs are potent tools for weight loss, they are not a magic cure and lasting health benefits likely depends on integrated behavioural management.